Clinical trials: Hepatocellular Cancer
Hepatocellular Carcinoma, Portal Vein Tumor Thrombus
TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT
Hepatocellular carcinoma (HCC) with main trunk portal vein tumor thrombus (PVTT) has poor prognosis. The main lethiferous factor is the upper gastrointestinal hemorrhage by PVTT-related portal hypertension, then the second is the…
- Conditions
- Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, Systemic Therapy
- Trial name
- NCT06622031
- Testing
- Transjugular intrahepatic portosystemic shunt, Lenvatinib, PD-1 inhibitor
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma
the purpose of this study is to evaluate the efficacy and safety of aptinib in patients with advanced HCC
- Trial name
- HCC (NCT03398122)
- Testing
- TACE, Apatinib
- Where
- China
- Volunteers
- 248 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
NAFLD, Hepatocellular Carcinoma
Utilization of MAsS in Patients Undergoing LT for HCC
The aim of this study is to determine the effects of liver transplantation and standard immunosuppression on body composition in patients with compensated cirrhosis and hepatocellular carcinoma.
- Conditions
- NAFLD, Hepatocellular Carcinoma, Liver Diseases, Liver Cancer
- Trial name
- NCT05184283
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Columbia University
Advanced Adult Hepatocellular Carcinoma
Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
The purpose of this study is to evaluate the safety and tolerability of dalantercept plus sorafenib in patients with advanced hepatocellular carcinoma (HCC) to determine the recommended dose level of dalantercept in combination…
- Trial name
- NCT02024087
- Testing
- Dalantercept plus sorafenib
- Where
- 7 sites in United States
- Volunteers
- 21 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Carcinoma, Hepatocellular
Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma
This is an open-label, integrated, Phase 1b/2 trial to determine the recommended Phase 2 dose (RP2D) and to evaluate the efficacy, safety, and pharmacokinetic of MSC2156119J as first-line treatment versus sorafenib in subjects…
- Trial name
- NCT01988493
- Testing
- Tepotinib 300 mg, Tepotinib 500 mg, Tepotinib 1000 mg
- Where
- 43 sites in China, South Korea and 1 more
- Volunteers
- 117 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Hepatocellular Carcinoma
Watch and Wait and Surgical Treatment for Clinical Complete Responders After Non-Curative Therapy for Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) accounts for more than 90% of primary liver cancers and is the sixth most common cancer in the world and ranked third in mortality.
- Trial name
- WATCH (NCT05349331)
- Testing
- Liver Resection
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Sun Yat-sen University
Localized Non-Resectable Adult Liver Carcinoma
Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study
This research registry studies Yttrium Y 90 resin microspheres in collecting data from patients with liver cancer not capable of being removed by surgery (unresectable) for the radiation-emitting Selective Internal…
- Trial name
- RESiN (NCT02685631)
- Testing
- Yttrium-90 Resin Microspheres
- Where
- 42 sites in United States
- Volunteers
- 1,653 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Hepatocellular Carcinoma, Liver Cancer
Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer
RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, Localized Unresectable Liver Cancer
- Trial name
- NCT01042041
- Testing
- sorafenib tosylate, doxorubicin hydrochloride, cisplatin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Liver Cancer, Neoplasms, Liver
Study of New Software Used During Ablations
Background: Ablation is a procedure that heats tumor tissue to a high temperature to destroy it. Doctors perform this procedure by putting a probe in the tumor. This delivers heat to the site.
- Conditions
- Liver Cancer, Neoplasms, Liver, Hepatic Neoplasms, Hepatic Cancer
- Trial name
- NCT01906021
- Testing
- CT/CBCT thermometry method, Ablation Probe
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Urothelial Carcinoma, Carcinoma, Non-Small Cell Lung
A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
This Phase 4, prospective, multicenter, non-interventional, regulatory post-marketing surveillance study will collect information on the the safety and effectiveness of atezolizumab under the clinical practice, and update the…
- Conditions
- Urothelial Carcinoma, Carcinoma, Non-Small Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Carcinoma
- Trial name
- NCT03232593
- Testing
- Atezolizumab
- Where
- 56 sites in South Korea
- Volunteers
- 1,758 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma
Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1
Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death and the second most deadly malignancy in Taiwan.
- Trial name
- NCT06354387
- Testing
- Alectinib (Alecensa), Nivolumab (Opdivo)
- Where
- Taiwan
- Volunteers
- 5 people
- Sponsor
- China Medical University Hospital
Hepatocellular Carcinoma, Secondary Malignant Neoplasm of Liver
Radioembolization of Primary and Secondary Liver Malignancies and The Effect On The Immune System
The goal of this study is to understand the immunologic effects radioembolization has on the immune system. This will be done by evaluating the changes on biopsy, peripheral blood monocytes, and cytokines.
- Trial name
- NCT03889093
- Testing
- Yttrium-90
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Minnesota
Carcinoma, Hepatocellular
Testing of ADI-PEG in Hepatocellular Carcinoma
Amino acid deprivation therapy is an effective means for the treatment of some forms of cancer. Recently it has been found that human hepatocellular carcinomas (HCC) cell lines appear to require arginine for growth.
- Trial name
- NCT00056992
- Testing
- ADI-PEG 20
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- FDA Office of Orphan Products Development
Hepatocellular Carcinoma
Study on Recurrence Monitoring of Hepatocellular Carcinoma With 5-Hydroxymethylcytosine Test
In this study, investigators aim to find out how plasma 5hmC level changes in hepatocellular carcinoma patients after liver resection, and determine whether 5hmC can be used as a biomarker for HCC recurrence monitoring.
- Trial name
- NCT03493763
- Testing
- 5hmC profile in plasma cell-free DNA after liver resection
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shanghai Zhongshan Hospital
Liver Cancer, Esophageal Cancer
Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
The investigators hypothesize that abnormalities in thromboelastography (TEG) parameters in patients with liver, pancreas, biliary, esophageal, colorectal, and lung adenocarcinoma can serve as biomarkers for oncologic disease…
- Conditions
- Liver Cancer, Esophageal Cancer, Colorectal Cancer, Lung Adenocarcinoma
- Trial name
- TEG (NCT05517811)
- Testing
- TEG indices
- Where
- 2 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Hepatocellular Carcinoma (HCC)
Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence
To assess 1-year recurrence-free survival (RFS) in patients with hepatocellular carcinoma (HCC) who are at high risk of Inguinal orchiectomy recurrence usingTACE combined with icaritin
- Trial name
- NCT06644937
- Testing
- TACE combined with Acoradine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhujiang Hospital
Hepatocellular Carcinoma
Substudy: Interconnection of Arterial Tumor Feeders Through Tumor Sinusoid in HCC
It is postulated that all arterial tumor feeders supplying a HCC tumor are interconnected with each other through the tumor sinusoid, such that when one of the feeders is catheterized for delivery of a liquid embolic agent, the…
- Trial name
- NCT04641637
- Testing
- TACE
- Where
- Hong Kong
- Volunteers
- 40 people
- Sponsor
- Chinese University of Hong Kong
Intrahepatic Cholangiocarcinoma (Icc)
Liquid Biopsy Using Exosomal miRNA Enables Risk Stratification of Potential Metastasis in Patients With Intrahepatic Cholangiocarcinoma.
Occult metastasis at the time of surgery is a major driver of poor outcomes in intrahepatic cholangiocarcinoma (ICC), yet reliable preoperative biomarkers to identify such patients are lacking.
- Trial name
- EXOMIC (NCT07224737)
- Testing
- EXOMIC small RNA sequencing, EXOMIC assay (qRT-PCR validation)
- Where
- United States
- Volunteers
- 230 people
- Sponsor
- City of Hope Medical Center
Unresectable Hepatocellular Carcinoma
Safety and Efficacy of Folic Acid Combined With Atezolizumab and Bevacizumab as First-Line Therapy for Unresectable Hepatocellular Carcinoma
This study is evaluating the safety and potential effectiveness of adding folic acid to atezolizumab plus bevacizumab as first-line treatment for adults with unresectable hepatocellular carcinoma (HCC).
- Trial name
- NCT07835737
- Testing
- Folic Acid, Atezolizumab & Bevacizumab
- Volunteers
- 78 people
- Sponsor
- West China Hospital
Hepatocellular Carcinoma (HCC)
TACE With Immune Agents for Angiogenesis in Hepatocellular Carcinoma
This study investigates the clinical efficacy and safety of transarterial chemoembolization (TACE) combined with the immune agent nivolumab compared to TACE alone for treating hepatocellular carcinoma (HCC).
- Trial name
- NCT07053202
- Testing
- Nivolumab, Transarterial Chemoembolization (TACE)
- Where
- China
- Volunteers
- 140 people
- Sponsor
- The First Hospital of Hebei Medical University